Cytovance Biologics launches standalone analytical services for biologics development
Wednesday, August 19, 2026
Cytovance Biologics has expanded its analytical services portfolio to provide standalone analytical support for biotechnology and pharmaceutical companies. The new offering gives clients access to Cytovance's analytical expertise and regulatory-ready solutions without requiring a manufacturing engagement.
With more than 20 years of experience in biologics development and manufacturing, Cytovance is making its analytical capabilities available to companies seeking additional laboratory and testing support.
The standalone services include analytical method development and transfer, method qualification and validation, product characterisation, release testing, stability studies and sample storage. Services are available under both GMP and non-GMP conditions and can support programmes from early development through commercialisation.
For early-stage biotechnology companies with limited internal laboratory resources, Cytovance provides analytical development support and established platform methods to help accelerate product characterisation and development. As programmes progress, GMP-compliant testing and stability services can support regulatory submissions, process validation and commercial preparation.
The company will provide flexible analytical support based on individual programme requirements, ranging from single studies and ongoing stability programmes to routine GMP testing.
Cytovance expects demand for U.S.-based analytical services to increase as biologics pipelines expand and companies seek reliable domestic partners. The new standalone offering expands the company's support for biologics developers while providing greater flexibility in development and manufacturing strategies.
Source: businesswire.com
